Phio submits FDA package for PH-762, plans Phase 2b study
Phio said it submitted a briefing package to the FDA for PH-762 and plans a Phase 2b neoadjuvant study after completing Phase 1b.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.